BioGend Therapeutics Co., Ltd. (TPEX:6733)

BioGend Therapeutics Revenue

BioGend Therapeutics had revenue of 59.49M TWD in the quarter ending June 30, 2026, with 12.85% growth. This brings the company's total for the last twelve months to 236.58M, up 21.31% year-over-year. In the year 2025, BioGend Therapeutics had annual revenue of 222.34M with 32.62% growth. That makes BioGend Therapeutics the 38,639th largest company in the world by revenue and 2,015th in Taiwan.

• Revenue (ttm): 236.58M
• Revenue Growth: +21.31%
• P/S Ratio: 13.46
• Revenue / Employee: n/a
• Employees: n/a
• Market Cap: 3.18B

Revenue Chart

Chart

Chart

Revenue by Geography

Chart

• Taiwan 218.69M 98.4%
• Hong Kong and Chinese Mainland 2.22M 1.0%
• Malaysia 1.43M 0.6%

Fiscal year ended Dec 31, 2025 See the full BioGend Therapeutics breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	222.34M	54.69M	32.62%
Dec 31, 2024	167.65M	57.74M	52.53%
Dec 31, 2023	109.91M	78.46M	249.51%
Dec 31, 2022	31.45M	22.18M	239.26%
Dec 31, 2021	9.27M	7.88M	565.40%

Data Source: S&P Global Market Intelligence Last updated: Aug 7, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 19, 2026

Data Sources Report a data error